A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary In-stent Restenosis

Coronary In-stent Restenosis Clinical Trial

Official title:
A Multicenter, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of Dissolve™ Compared to SeQuent® Please in Treatment of Coronary In-stent Restenosis in Chinese Population

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of treatment of coronary in-stent restenosis by Paclitaxel-eluting balloon catheter Dissolve™ versus SeQuent®Please, and the reference diameter of coronary artery stenosis is 2.5mm-4.0mm and the length ≤ 26mm.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Coronary In-stent Restenosis

Clinical Trial Details

NCT number	NCT03373695
Study type	Interventional
Source	DK Medical Technology (Suzhou) Co., Ltd.
Contact
Status	Active, not recruiting
Phase	N/A
Start date	February 22, 2018
Completion date	September 4, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT00852176` - Retrospective Long-term Safety and Efficacy Study of the Beta-Cath(TM) 3.5F System
Recruiting	`NCT03069066` - Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment With Scoring Balloon Pre-dilatation (RIBS VI Scoring)	Phase 4
Recruiting	`NCT04213378` - Evaluation of the Efficacy and Safety of a Paclitaxel Eluting PTCA Balloon Catheter in Coronary In-stent Restenosis	Phase 2/Phase 3
Not yet recruiting	`NCT02672878` - Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment (RIBS VI)	Phase 4